UPPER GASTROINTESTINAL SAFETY WITH THE BUFFERED SOLUTION OF ALENDRONATE 70 MG: POST-MARKETING EXPERIENCE

被引：0
|
作者：
Hruska, J. [1 ]
Jorgensen, F. K. [2 ]
Pierleoni-Nielsen, C. [2 ]
Eriksen, E. F. [3 ]
机构：
[1] McDACom GmbH, Zurich, Switzerland
[2] Klifo AS, Glostrup, Denmark
[3] Oslo Univ Hosp, Dept Clin Endocrinol, Oslo, Norway
来源：
OSTEOPOROSIS INTERNATIONAL | 2017年 / 28卷
关键词：
OSTEOPOROSIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P589
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [41] Analysis of fomepizole safety based on a 16-year post-marketing experience in France
    Rasamison, Riana
    Besson, Helene
    Berleur, Marie-Pierre
    Schicchi, Azzurra
    Megarbane, Bruno
    CLINICAL TOXICOLOGY, 2020, 58 (07) : 742 - 747
  • [42] Post-Marketing Safety Experience with Edoxaban in Japan for Thromboprophylaxis Following Major Orthopedic Surgery
    Kuroda, Yasufumi
    Hotoda, Hitoshi
    Nishikawa, Yasuhiro
    Nishiwaki, Akinori
    BLOOD, 2012, 120 (21)
  • [43] Effect of Buffered Solution of Alendronate 70mg on Bone Mineral Density and Bone ALP: Prospective Observational Study
    Giusti, Andrea
    Black, Dennis M.
    Barone, Antonella
    Hruska, Josef
    Bianchi, Gerolamo
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 286 - 286
  • [44] Herpes zoster vaccine live: A 10 year review of post-marketing safety experience
    Willis, English D.
    Woodward, Meredith
    Brown, Elizabeth
    Popmihajlov, Zoran
    Saddier, Patricia
    Annunziato, Paula W.
    Halsey, Neal A.
    Gershon, Anne A.
    VACCINE, 2017, 35 (52) : 7231 - 7239
  • [45] Post-Marketing Safety Experience of Vedolizumab in Patients With Pre-existing Viral Hepatitis
    Wu, Deng-Chyang
    Hilmi, Ida Normiha
    Adsul, Shashi
    Blake, Aimee
    Bhayat, Fatima
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S393 - S393
  • [46] Near Real-Time Post-Marketing Surveillance: The Experience of the Vaccine Safety Datalink
    Yih, W. K.
    Fireman, B.
    Klein, N.
    Kulldorff, M.
    Lewis, E.
    Lieu, T.
    Weintraub, E.
    Platt, R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S5 - S6
  • [47] Two-year gastrointestinal safety and tolerability of alendronate 70mg once weekly.
    Genco, RJ
    Van Dyke, T
    Leung, A
    Meng, L
    Ritter, S
    Grossman, S
    Salzmann, G
    Lombardi, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S528 - S528
  • [48] REPORT ON A CONFERENCE - POST-MARKETING DRUG SAFETY MONITORING
    CLARKNIEUWLAND, K
    DEHAEN, F
    TEIRLYNCK, O
    HEALTH POLICY, 1989, 11 (03) : 239 - 241
  • [49] Eslicarbazepine acetate: update of post-marketing safety data
    Vieira, M.
    Gama, H.
    Graca, J.
    Costa, R.
    Sousa, R.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 773 - 773
  • [50] Post-marketing Safety profile of ferric carboxymaltose (FERINJECT®)
    Chenaf, C.
    Pagani, M.
    Parry, E.
    Jonville-Bera, A. P.
    Lagarce, L.
    Jean-Pastor, M. J.
    Tonnay, V.
    Eschalier, A.
    Zenut, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 101 - 101
12345